Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
32dKdf1AXUrYBvB7
